November 28, 2020

The Niche

Knoepfler lab stem cell blog

Month: August 2014

13 min read

StemCells Inc. is a top biotech company developing stem cell-based therapies. They have a deep pipeline that includes already ongoing trials for a variety of diseases. I invited company leadership to do an interview and they graciously accepted. Below is the interview with CFO Greg Schiffman (picture at left from LinkedIn) including what I thought were some tough questions from me and very detailed answers from Shiffman. Thank you, Greg. 1. Where does the company stand today in terms of product development, capitalization, and …Read More

2 min read

A mysterious organization called BioGatekeeper, Inc. has filed a legal challenge to the Yamanaka Patent seeking to cancel it (for more on this see here and here). The technology to change just about any human cell into a super powerful kind of stem cell called induced pluripotent stem cells (iPS cells or iPSC) has great potential not only to help millions of patients, but also to make companies millions or even billions of dollars. Many scientists have been on the trail of cellular reprogramming, …Read More

3 min read

The BioTime subsidiary, Asterias, has received FDA approval for a combined Phase I/IIa clinical trial of OPC1 for treating spinal cord injury. BioTime (BTX) and Asterias (ASTY) have picked up the portfolio of the former Geron clinical trial using oligodendrocyte precursor cells (OPC). Asterias also acquired a second element from Geron in the form of a lung cancer treatment based on stem cells that sounds quite intriguing. To learn more about this exciting news I interviewed Jane Lebkowski, President of Research and Development at Asterias. 1. …Read More

2 min read

Who should you follow on Twitter amongst all the biologists out there? Actually, it very much depends on your interests and what you want to get out of it. Below is my list of top biologists/biology writers that I, with all my many biases (see below) recommend to you to follow on Twitter, in no particular order (actually alphabetized). Check out their Tweets. Engage them with a question or reply to them with a valuable link. See what happens. The nice thing about Twitter is you can essentially …Read More